Natural killer and lymphokine activated killer cell functions in Hodgkin's disease
- PMID: 2386735
- PMCID: PMC1971824
- DOI: 10.1038/bjc.1990.261
Natural killer and lymphokine activated killer cell functions in Hodgkin's disease
Abstract
We report the natural killer (NK) and lymphokine activated killer (LAK) cell activities in peripheral blood lymphocytes (PBL) from untreated patients with Hodgkin's disease (HD) and from healthy donors. The frequency of LAK cell precursors was also studied using limiting dilution analysis (LDA). About 75% of the HD patients had normal NK activity. There was a higher percentage of low NK responders (mean percent NK activity of healthy donors--2 SD) in patients with lymphocyte depletion histologic grade of the disease and those who were in clinical stage IV, suggesting a correlation of decrease in NK activity with poor prognosis. We found efficient LAK activity against the NK-sensitive K562 cells and NK-resistant VIP (melanoma) and T-24 (bladder carcinoma) tumour targets in both low and normal NK responder HD patients, irrespective of the histopathological grade and clinical stage of the disease. In concordance with their good LAK cell activity, HD patients showed a frequency distribution of LAK cell progenitors in the PBL comparable to that of healthy donors.
Similar articles
-
Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia.Cancer Immunol Immunother. 1990;31(1):44-8. doi: 10.1007/BF01742494. Cancer Immunol Immunother. 1990. PMID: 2306755 Free PMC article.
-
Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.Cancer. 1993 Feb 15;71(4):1313-21. doi: 10.1002/1097-0142(19930215)71:4<1313::aid-cncr2820710424>3.0.co;2-#. Cancer. 1993. PMID: 7679609
-
Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.Clin Immunol Immunopathol. 1995 Oct;77(1):75-81. doi: 10.1016/0090-1229(95)90139-6. Clin Immunol Immunopathol. 1995. PMID: 7554487
-
[Natural killer cell activity, activity of lymphokine activated killer cells (LAK activity), killer helper factor (KHF)].Nihon Rinsho. 1999 Nov;57 Suppl:666-9. Nihon Rinsho. 1999. PMID: 10635943 Review. Japanese. No abstract available.
-
Natural killer cells, lymphokine-activated killer cells, and cytolytic T lymphocytes: compartmentalization of age-related changes in cytolytic lymphocytes?J Gerontol. 1994 May;49(3):B85-92. doi: 10.1093/geronj/49.3.b85. J Gerontol. 1994. PMID: 8169331 Review. No abstract available.
Cited by
-
TREM2 promotes natural killer cell development in CD3-CD122+NK1.1+ pNK cells.BMC Immunol. 2021 May 12;22(1):30. doi: 10.1186/s12865-021-00420-0. BMC Immunol. 2021. PMID: 33980160 Free PMC article.
-
Natural killing activity in patients with spontaneous regression of malignant lymphoma.J Clin Immunol. 1996 Nov;16(6):334-9. doi: 10.1007/BF01541669. J Clin Immunol. 1996. PMID: 8946278
-
Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma.Front Immunol. 2018 Feb 14;9:267. doi: 10.3389/fimmu.2018.00267. eCollection 2018. Front Immunol. 2018. PMID: 29491867 Free PMC article. Review.
-
Axl signaling induces development of natural killer cells in vitro and in vivo.Protoplasma. 2017 Mar;254(2):1091-1101. doi: 10.1007/s00709-016-1016-5. Epub 2016 Aug 22. Protoplasma. 2017. PMID: 27549806
-
Clinical significance of natural killing activity in patients with advanced lymphoma.J Clin Immunol. 1998 Mar;18(2):132-41. doi: 10.1023/a:1023298917191. J Clin Immunol. 1998. PMID: 9533657
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical